Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases


Airway diseases, such as Asthma and Chronic Obstructive Pulmonary Disease (COPD), constitute a major health burden worldwide. It is estimated, for example, that nearly 15.0% of the adult population in the US are affected with such diseases, and the economic cost burden is over $23 billion annually. Unfortunately, the current options for treatment of such diseases are quite limited, consisting only of bronchodilators and inhaled steroids. The need for a novel and more effective class of therapeutics agents is imperative. The subject invention provides for a potentially more specific and effective treatment of airway diseases as compared with existing treatments. It is based on the inhibition of Hyaluronan (HA), a structural polysaccharide that plays a role in the signaling pathway that leads to the onset of airway diseases. Such inhibition blocks the development of airway inflammation and airway hyperresponsiveness (AHR), two of the components associated with airway diseases, and thus may be useful in the treatment of such diseases. The invention discloses two antagonists of HA, i.e. heparosan, and Hyaluronan oligosaccharides (oHAs). Their administration to a human subject in need can be accomplished via the use of an inhaler or nebulizer.

Potential Commercial Applications: Competitive Advantages:
  • Effective treatment of airway diseases
 
  • Potentially cost-effective treatment for airway diseases, with higher specificity and reduced side effect as compared to existing treatments


Development Stage:
In vitro data available

Inventors:

Stavros Garantziotis (NIEHS)  ➽ more inventions...

John Hollingsworth

Bryan Toole

Jian Liu


Intellectual Property:
U.S. Pat: 9,717,752 issued 2017-08-01
PCT Application No. PCT/US2013/029776
US Application No. 14/398,837
Various international patent applications pending

Collaboration Opportunity:

The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of hyaluronan antagonists to treat chronic respiratory diseases. For collaboration opportunities, please contact Sally E. Tilotta, Ph.D. at sally.tilotta@nih.gov.


Licensing Contact:
Uri Reichman, Ph.D., M.B.A.
Email: uri.reichman@nih.gov
Phone: 301-435-4616

OTT Reference No: E-080-2012/0
Updated: Oct 3, 2017